Inspire Medical Q3 revenue $203.2M (+33% YoY), EPS $0.60 vs loss, raises FY guidance

Inspire Medical Systems, Inc.

2024-Q3 EPS reported $0.60 revenue$563,086,000

Revenue $203.2M, up 33% YoY; U.S. revenue $195.8M (+33%), OUS $7.4M (+27%).
Operating income $14.3M vs loss $13.5M; net income $18.5M, diluted EPS $0.60 vs loss $0.29.
Raises FY 2024 revenue guidance to $793-798M (27-28% growth) and EPS guidance to $1.20-1.40.
Activated 66 new U.S. centers (total 1,371); created 13 new sales territories (total 323).
Received FDA approval for Inspire V neurostimulation system; gross margin steady at 84.1%.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.